Table 1.
Overall (N=24) | Surviving Participants (N=16) |
Deceased Participants (N=8) |
|
---|---|---|---|
Age | 54.25 ± 8.9 | 55.19 ± 6.46 | 52.38 ± 12.83 |
Sex | |||
Male | 14 (58.33%) | 10 (62.50%) | 4 (50.00%) |
Female | 10 (41.67%) | 6 (37.50%) | 4 (50.00%) |
ECOG | |||
0 | 13 (54.17%) | 12 (75.00%) | 1 (12.50%) |
1 | 11 (45.83%) | 4 (25.00%) | 7 (87.50%) |
Treatment | |||
Dabrafenib + trametinib | 3 (12.50%) | 2 (12.50%) | 1 (12.50%) |
Vemurafenib + cobimetinib | 21 (87.50%) | 14 (87.50%) | 7 (87.50%) |